Abstract
HIV incidence in eastern and southern Africa has historically been concentrated among girls and women aged 15-24 years, but as new cases decline with HIV interventions, population-level infection dynamics may shift by age and gender. Here, we integrated population-based surveillance and longitudinal deep-sequence viral phylogenetics to assess how HIV incidence and the population groups driving transmission have evolved over a 15 year period from 2003 to 2018 in Uganda. HIV viral suppression increased more rapidly in women than men, resulting in 1.5-2 fold higher suppression rates in women with HIV by 2018 across age groups. Incidence declined more slowly in women than men, increasing pre-existing gender imbalance in HIV burden. Age-specific transmission flows shifted; the share of transmission to girls and women aged 15-24 years from older men declined by approximately one third, whereas the contribution of transmission to women aged 25-34 years from men aged 0-6 years older doubled from 2003 to 2018. We estimated closing the gender gap in viral suppression could have reduced HIV incidence in women by half in 2018 and ended gender disparities in incidence. This study suggests that male-targeted HIV programs to increase HIV suppression are critical to reduce incidence in women, close gender gaps in infection burden and improve men’s health in Africa.
Competing Interest Statement
Dr. Wawer and Dr. Gray are paid consultants to the Rakai Health Sciences Program and serves on its Board of Directors. This arrangement has been reviewed and approved by the Johns Hopkins University in accordance with its conflict of interest policies.
Funding Statement
This study was supported by the Bill & Melinda Gates Foundation; the National Institute of Allergy and Infectious Diseases; the National Institute of Mental Health; the National Institute of Child Health and Development; the Division of Intramural Research of the National Institute for Allergy and Infectious Diseases; the National Heart, Lung, and Blood Institute; the Fogarty International Center; the World Bank; the Doris Duke Charitable Foundation; the Johns Hopkins University Center for AIDS Research; the U.S. President's Emergency Plan for AIDS Relief (PEPFAR) through the Centers for Disease Control and Prevention; the Engineering and Physical Sciences Research Council through the EPSRC Centre for Doctoral Training in Modern Statistics and Statistical Machine Learning at Imperial and Oxford; and the Imperial College London President's PhD Scholarship fund.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study was independently reviewed and approved by the Ugandan Virus Research Institute, Scientific Research and Ethics Committee, protocol GC/127/13/01/16; the Ugandan National Council of Science and Technology; and the Western Institutional Review Board, protocol 200313317. All study participants provided written informed consent at baseline and follow-up visits using institutional review board approved forms. This project was reviewed in accordance with CDC human research protection procedures and was determined to be research, but CDC investigators did not interact with human subjects or have access to identifiable data or specimens for research purposes.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
Corrected URL to Data/Code
Data Availability
The deep-sequence phylogenies and basic individual-level data analysed during the current study are available at https://github.com/MLGlobalHealth/phyloSI-RakaiAgeGender. HIV-1 reads are available on reasonable request through the PANGEA-HIV consortium. Please contact project manager Lucie Abeler-Dörner (lucie.abeler-dorner@bdi.ox.ac.uk) for further details. Additional individual-level data are available on reasonable request to RHSP.
